Nivolumab vs Sars-Cov-2 Virus Spike Protein
Nivolumab vs Sars-Cov-2 Virus Spike Protein: Overview
This comparison examines the pharmacological differences between Nivolumab and Sars-Cov-2 Virus Spike Protein.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Pharmacokinetics
Half-life: Nivolumab β 27 days.
Chemical Properties
Type: Nivolumab β Antibody; Sars-Cov-2 Virus Spike Protein β Vaccine component.